P2RX7 and central nervous system cancer: The oncological conditions, in which P2X7 receptor antagonism were efficacious in reducing cancer progression include, but are not limited to, breast cancer [88,89], melanoma [90,91,92], neuroblastoma [20], mesothelioma [8], glioma [93] and AML [79,80,81,92].